Mechanism Of Action:
Active form of fingolimod binds to sphingosine 1-phosphate receptors 1, 3, 4, and 5. And blocks the lymphocytes’ ability to emerge from lymph nodes; therefore, the number of lymphocytes available to the CNS is decreased, which reduces central inflammation.
Indication:
Fingolimod is indicated for the treatment of relapsing types of MS including: clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease, in patients ≥10 years of age.
